Cardiology
Cardiovascular effects of cancer therapy
Emerging evidence with 100 primary claims
Specific, answerable questions in this area — each with its own synthesized evidence and consensus. Open one to see the forest plot, source trials, and how the consensus has changed over time.
Does methacycline vs placebo improve outcomes in Cardiotoxicity?
Low Certainty+ Favors benefitmethacycline vs placebo · Cardiac Index
Does anticoagulants vs placebo improve outcomes in Malignant Neoplasms?
Low Certainty+ Favors benefitanticoagulants vs placebo · Myocardial Infarction Hospitalization
Does carvedilol vs doxorubicin improve Cardiac Index in Malignant neoplasm of breast?
Low Certainty− Favors harmcarvedilol vs doxorubicin · Cardiac Index
Does immune checkpoint inhibitors vs placebo improve outcomes in cancer therapy-related cardiovascular toxicity?
Low Certainty− Favors harmimmune checkpoint inhibitors vs placebo · Cardiac Index
Does radiopharmaceutical vs placebo improve Myocardial Infarction Hospitalization in Response Evaluation Criteria in Solid Tumors?
Low Certainty− Favors harmradiopharmaceutical vs placebo · Myocardial Infarction Hospitalization
Does doxorubicin vs placebo improve outcomes in Cardiotoxicity?
Low Certainty− Favors harmdoxorubicin vs placebo · Cardiac Index
Does candesartan vs doxorubicin improve Cardiac Index in Malignant neoplasm of breast?
Low Certainty− Favors harmcandesartan vs doxorubicin · Cardiac Index
Does doxorubicin vs placebo improve Cardiac Index in Cardiotoxicity?
Low Certainty− Favors harmdoxorubicin vs placebo · Cardiac Index
Does dalteparin vs coumarin improve outcomes in Malignant Neoplasms?
Low Certainty− Favors harmdalteparin vs coumarin · Left Ventricular Ejection Fraction
Cardio-oncology (also known as onco-cardiology, cancer cardiotoxicity, chemotherapy heart). Cardiovascular effects of cancer therapy
Synapse tracks 9 specific clinical questions in Cardio-oncology, each synthesized independently from its own trial evidence. They include: "Does methacycline vs placebo improve outcomes in Cardiotoxicity?"; "Does anticoagulants vs placebo improve outcomes in Malignant Neoplasms?"; "Does carvedilol vs doxorubicin improve Cardiac Index in Malignant neoplasm of breast?"; "Does immune checkpoint inhibitors vs placebo improve outcomes in cancer therapy-related cardiovascular toxicity?"; "Does radiopharmaceutical vs placebo improve Myocardial Infarction Hospitalization in Response Evaluation Criteria in Solid Tumors?".
As of 2026-06-25, the scientific consensus on Cardio-oncology is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.
This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/69b0a31db42209bc31dca358.
Deterministic synthesis from Synapse's enriched corpus — 128 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.
Explore every Cardio-oncology paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.
Search Cardio-oncology papersPowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers